Home › Bronchiolitis Obliterans Syndrome › Massachusetts
Bronchiolitis Obliterans Syndrome clinical trials in Massachusetts
14 studies for Bronchiolitis Obliterans Syndrome are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07011810A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
- Dana-Farber Cancer Institute- Site Number : 8400007, Boston
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Sep 22, 2026 · NCT07116031Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT05996627A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT06585774Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
- Massachusetts Cancer Research Center, Boston
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT05919511Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 2 and older · All sexes · Updated Jul 23, 2026 · NCT06991361Plasma and Radiologic Biomarkers of Response to ECP in Lung Transplant Recipients With CLAD
- Massachusetts General Hospital, Boston
- Brigham and Women's Hospital, Boston
RecruitingObservational study
Ages 7 and older · All sexes · Updated Jul 14, 2026 · NCT07434869A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- Massachusetts General Hospital, Boston
RecruitingPhase 2
Ages 2 and older · All sexes · Updated Jun 16, 2026 · NCT04710576BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
- Dana-Farber Cancer Institute, Boston
- Boston Children's Hospital, Boston
- Brigham and Women's Hospital, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT05922761A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06615050Direct to Patient Minimal Risk Biospecimen and Data Collection Research
- Joined Bio, Lexington
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 90 · All sexes · Updated May 5, 2026 · NCT07128966Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Mar 11, 2026 · NCT05236062A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 15, 2025 · NCT06462365From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.